Andere Kunden interessierten sich auch für
![Molecular Genetics of Core Binding Factor Acute Myeloid Leukemia]( "Molecular Genetics of Core Binding Factor Acute Myeloid Leukemia")
Molecular Genetics of Core Binding Factor Acute Myeloid Leukemia36,99 €![Genetic Variations in Acute Promyelocytic Leukemia patient]( "Genetic Variations in Acute Promyelocytic Leukemia patient")
Genetic Variations in Acute Promyelocytic Leukemia patient48,99 €![Acute lymphoblastic leukemia (ALL) and interferon beta-1 gene]( "Acute lymphoblastic leukemia (ALL) and interferon beta-1 gene")
Acute lymphoblastic leukemia (ALL) and interferon beta-1 gene44,99 €![From the cell to molecular markers]( "From the cell to molecular markers")
From the cell to molecular markers50,99 €![Detection of some AML Fusion Genes by Molecular Biology Technique]( "Detection of some AML Fusion Genes by Molecular Biology Technique")
Detection of some AML Fusion Genes by Molecular Biology Technique32,99 €![Molecular markers associated with barley improvement]( "Molecular markers associated with barley improvement")
Molecular markers associated with barley improvement26,99 €![Molecular Genetic Markers for Salt Tolerance in Some Egyptian Barley]( "Molecular Genetic Markers for Salt Tolerance in Some Egyptian Barley")
Molecular Genetic Markers for Salt Tolerance in Some Egyptian Barley42,99 €
Acute myeloid leukemia is a malignant disease of the hematopetic system. It often leads to a massive proliferation of precoursors of myelopoiesis in the bone marrow and blood. Based on the morphology of the immature blood cells and their differentiation AMLs are stratificated into eight sub-goups using the French-American-British classification (FAB). Despite classification, generating a prognosis for the patient is often difficult, which in turn makes the selection of the appropriate treatment more difficult. Prognosis is mainly based upon age, white-cell count and on cytogenetics of patients. The cytogenetic classification into the risk groups favorable, intermediate and unfavorable determines the intensity of therapy. In the intermediate group most patients have a normal karyotype, but their progress of disease is very variable. For this reason it is intended to search for novel prognostic, molecular markers which give a more accurate prediction of the progression of disease.